Quantcast

Latest Telik Inc. Stories

2010-01-25 14:53:00

PALO ALTO, Calif., Jan. 25 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the initiation of a Phase 1 clinical study to evaluate ezatiostat hydrochloride (TELINTRA, TLK199) tablets in combination with lenalidomide (Revlimid) in patients with Myelodysplastic Syndrome (MDS). This Phase 1 trial is an open label, multicenter, dose escalation study of TELINTRA in combination with lenalidomide in patients with non-deletion (5q-) low to intermediate-1 risk MDS. TELINTRA...

2009-11-13 15:05:00

PALO ALTO, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $6.1 million, or $0.11 per share, for the third quarter ended September 30, 2009, compared with a net loss of $8.0 million, or $0.15 per share, for the comparable period in 2008. For the quarter ended September 30, 2009, total operating costs and expenses were $6.2 million, compared with $7.8 million in the 2008 third quarter. Operating expenses in the 2009 third quarter included...

2009-10-01 15:05:00

PALO ALTO, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10. Data on this study were presented at the 98th annual meeting of the...

2009-09-15 15:05:00

PALO ALTO, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that company management will provide a corporate overview at the UBS Global Life Sciences Conference in New York City on Tuesday, September 22, 2009 at 11:30 a.m. Eastern time (8:30 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on...

2009-08-06 15:05:00

PALO ALTO, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $5.7 million, or $0.11 per share, for the second quarter ended June 30, 2009, compared with a net loss of $13.6 million, or $0.26 per share, for the comparable period in 2008. For the quarter ended June 30, 2009, total operating costs and expenses were $6.3 million, compared with $11.0 million in the 2008 second quarter. Operating expenses in the 2009 second quarter included...

2009-08-03 14:14:00

PALO ALTO, Calif., Aug. 3 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced that the positive results from a Phase 1 multicenter, dose escalation study of ezatiostat hydrochloride (TELINTRA, TLK199) tablets in patients with Myelodysplastic Syndrome (MDS) have been published in a leading peer reviewed journal, Blood, 25 June 2009; Vol. 113, No. 26, pp. 6533-6540. Positive results from a separate Phase 1-2a study in MDS patients involving an intravenous formulation of...

2009-06-04 20:00:00

PALO ALTO, Calif., June 4 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that company management will provide a corporate overview at the Eighth Annual Needham Life Sciences Conference in New York City on Wednesday, June 10, 2009 at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on...

2009-05-31 17:00:00

PALO ALTO, Calif., May 31 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today announced presentation at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, of results from the ASSIST-5 Phase 3 randomized, multinational study of TELCYTA(R) (canfosfamide HCl) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD alone in second-line therapy in platinum refractory or resistant ovarian cancer. Study Design: Patients with...

2009-05-21 15:05:00

PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting of the American Society of Clinical Oncology (ASCO) which will be held from May 29 to June 2 in Orlando, FL. Details of the presentation are as follows: -- Abstract #5552 - General Poster...

2009-05-07 15:05:00

PALO ALTO, Calif., May 7 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) today reported financial results for the first quarter ended March 31, 2009. The net loss for the quarter ended March 31, 2009, was $7.7 million, or $0.14 per share, compared with a net loss of $9.8 million, or $0.19 per share, for the same period in 2008. As of March 31, 2009, cash, cash equivalents, restricted cash and investments totaled $57.3 million, compared with $63.5 million for the quarter ended...


Word of the Day
callithump
  • A somewhat riotous parade, accompanied with the blowing of tin horns, and other discordant noises; also, a burlesque serenade; a charivari.
'Callithump' is a back-formation of 'callithumpian,' a 'fanciful formation' according to the Oxford English Dictionary. However, the English Dialect Dictionary, says 'Gallithumpians' is a Dorset and Devon word from the 1790s that refers to 'a society of radical social reformers' or 'noisy disturbers of elections and meetings.'
Related